The Biology of Extending Survival in Advanced CRC

EP. 1: Early- Versus Late-Onset Colorectal Cancer

July 13th 2017

EP. 2: Colorectal Cancer Prevention and Screening: An Update

July 13th 2017

EP. 3: Prognostic/Predictive Value of Tumor-Sidedness in CRC

July 13th 2017

EP. 4: Nuances in Antibody Selection: Left Vs Right-Sided mCRC

July 13th 2017

EP. 5: Frontline Decisions in RAS Wild-Type Left-Sided mCRC

July 13th 2017

EP. 6: Maintenance and Second-Line Decisions in mCRC

July 13th 2017

EP. 7: Exploring Global Variations in Molecular Profiling

July 13th 2017

EP. 8: IDEA Trial: 3 vs 6 Months of Adjuvant Therapy in CRC

July 13th 2017

EP. 9: Global Perspectives and Initial Decisions in mCRC

July 13th 2017

EP. 10: Exploring Second-Line Therapeutic Options in mCRC

July 13th 2017

EP. 11: Sequencing Considerations in MSS CRC Tumors

July 13th 2017

EP. 12: Patient Selection for Regorafenib in CRC

July 13th 2017

EP. 13: Role of Trifluridine/Tipiracil in CRC

July 13th 2017

EP. 14: Pembrolizumab in MSI-H CRC Tumors

July 13th 2017

EP. 15: CRC: Emerging Immunotherapy Strategies in MSS Tumors

July 13th 2017

EP. 16: Evidence in BRAF-Mutant CRC Tumors

July 13th 2017

EP. 17: HER2 Status in Colorectal Cancer

July 13th 2017